Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy

Yamazaki, Shigeo; Sekine, Ikuo; Matsuno, Yoshihiro; Takei, Hidefumi; Yamamoto, Noboru; Kunitoh, Hideo; Ohe, Yuichiro; Tamura, Tomohide; Kodama, Tetsuro; Asamura, Hisao; Tsuchiya, Ryosuke; Saijo, Nagahiro

doi:10.1016/j.lungcan.2005.01.008

Cited by 106 publications

(85 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty subjects were treated with cisplatin and all five responders according to RECIST were classified as G3-LCNEC. This result is in keeping with previous publications, which reported 50% or more objective response rate of cisplatin-based chemotherapy in case of poorly differentiated NEN (Moertel et al 1991, Mitry et al 1999, Yamazaki et al 2005, Hainsworth et al 2006) in contrast to !15% for well-differentiated tumors (Moertel et al 1991, Mitry et al 1999. The added value of cisplatin-based chemotherapy in G3-WDNET remains to be better determined in the prospective setting.…”

Section: Discussionsupporting

confidence: 93%

“…For instance, the absence of midgut primaries and male predominance do not mirror classic metastatic low-grade well-differentiated GEP neoplasms in which ileum is the most frequent primary location and sex ratio is around one. This point is even better illustrated by the median OS of our patients, which is higher than the 8-month median OS usually observed in metastatic poorly differentiated NEC (Moertel et al 1991, Mitry et al 1999, Yamazaki et al 2005, Hainsworth et al 2006 but is still lower than expected for metastatic well-differentiated GEP-NEN, for which the 5-year survival is about 50% (Durante et al 2009.…”

Section: Discussioncontrasting

confidence: 52%

“…In addition, the differentiation status constitutes a predictive factor of response to cisplatin-based chemotherapy (Mitry et al 1999, Pavel et al 2012. Several studies demonstrated that poorly differentiated NEN respond to cisplatin in more than 50% of cases against !15% for well-differentiated ones (Moertel et al 1991, Mitry et al 1999, Yamazaki et al 2005, Hainsworth et al 2006.…”

mentioning

confidence: 98%

See 2 more Smart Citations

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Vélayoudom-Céphise

Duvillard²,

Foucan³

et al. 2013

Endocrine-Related Cancer

304

271

View full text Add to dashboard Cite

The new WHO classification of gastroenteropancreatic (GEP) neuroendocrine tumors (NET) implies that G3 neoplasms with mitotic index O20 and/or Ki67 index O20% are neuroendocrine carcinomas (NEC), described as poorly differentiated, small or large cell types, by analogy with lung NEC. To characterize the subgroup of non-small-cell-type GEP and thoracic NET with mitotic index O20 and/or Ki67 O20% according to their pathological features, response to cisplatin and overall survival (OS). We reviewed pathological and clinical presentation of G3 non-small-cell-type NET referred to our institution for 5 years. Data from 166 patients with metastatic thoracic and GEP-NET were collected. Twenty-eight patients (17%) fulfill the inclusion criteria. Tumors were classified as well-differentiated NET (G3-WDNET) in 42.8% of cases and poorly differentiated, large-cell NEC (G3-LCNEC) in 57.2% of cases. Plasma chromogranin A or neuron-specific enolase were elevated in 42 and 25% respectively of G3-WDNET and 31 and 50% of G3-LCNEC. Somatostatin receptor scintigraphy was positive in 88 and 50% of G3-WDNET or G3-LCNEC respectively. Complete or partial response to cisplatin was observed in 31% of cases, all classified as G3-LCNEC. The median OS was 41 months for G3-WDNET but 17 months for G3-LCNEC (PZ0.34). Short survival was observed in 25% of G3-WDNET but 62.5% of G3-LCNEC patients (PZ0.049). G3 ENETS GEP and thoracic neuroendocrine neoplasms (NEN) could constitute a heterogeneous subgroup of NEN as regards diagnosis, prognosis, and treatment. If confirmed, future classifications may consider splitting them into two groups according to their morphological differentiation.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussioncontrasting

confidence: 52%

mentioning

confidence: 98%

See 1 more Smart Citation

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Vélayoudom-Céphise

Duvillard²,

Foucan³

et al. 2013

Endocrine-Related Cancer

304

271

View full text Add to dashboard Cite

show abstract

“…Studies of adjuvant therapy in LCNEC have been few, with small series of patients, although some have shown satisfactory response to chemotherapy (17).…”

Section: Discussionmentioning

confidence: 99%

Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma

Iyoda

Travis

Sarkaria

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

“…A previous study indicated that solvent-based paclitaxel plus carboplatin may be active in SCLC that is refractory to the above-based regimens (21). Previous studies have reported that the clinical behavior and prognosis of LCNEC are similar to those of SCLC, and that SCLC-based regimens are effective in patients with LCNEC (22,23). Therefore, it appears to be reasonable to conclude that nab-paclitaxel combined with carboplatin is a useful option for the treatment of thymic LCNEC that is refractory to SCLC-based regimens.…”

Section: A B Cmentioning

confidence: 99%

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract. Thymic large cell neuroendocrine carcinomas (LCNECs) are rare, and the optimal regimen for second and subsequent lines of chemotherapy for the treatment of LCNECs remains unknown. In the present case study, a 59-year-old male with post-operative recurrent thymic LCNEC was treated with nab-paclitaxel and carboplatin every 4 weeks as third-line chemotherapy, and a partial response was achieved following 4 cycles of this regimen. The patient developed grade 4 neutropenia and grade 3 leukopenia, but none of the other toxicities, including peripheral neuropathy, were severe. Therefore, the patient was able to tolerate this salvage chemotherapy. To the best of our knowledge, the present study is the first case demonstrating clinically meaningful antitumor activity by combination chemotherapy with carboplatin and nab-paclitaxel, resulting in a positive response in a patient with thymic LCNEC.

show abstract

Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy

Cited by 106 publications

References 19 publications

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Contact Info

Product

Resources

About